Biogen (BIIB131 Drug) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Biogen (BIIB131 Drug) General Information
Description
An investigational drug for the treatment of acute ischemic stroke.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
- Cambridge, MA
- United States
Primary Industry
Buildings and Property
Acquirer
Corporate Office
- Cambridge, MA
- United States
Biogen (BIIB131 Drug) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biogen (BIIB131 Drug) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biogen (BIIB131 Drug) FAQs
-
Where is Biogen (BIIB131 Drug) headquartered?
Biogen (BIIB131 Drug) is headquartered in Cambridge, MA.
-
What industry is Biogen (BIIB131 Drug) in?
Biogen (BIIB131 Drug)’s primary industry is Buildings and Property.
-
Is Biogen (BIIB131 Drug) a private or public company?
Biogen (BIIB131 Drug) is a Private company.
-
What is Biogen (BIIB131 Drug)’s current revenue?
The current revenue for Biogen (BIIB131 Drug) is .
-
Who are Biogen (BIIB131 Drug)’s investors?
Biogen has invested in Biogen (BIIB131 Drug).
-
When was Biogen (BIIB131 Drug) acquired?
Biogen (BIIB131 Drug) was acquired on 11-Jan-2024.
-
Who acquired Biogen (BIIB131 Drug)?
Biogen (BIIB131 Drug) was acquired by CORXEL Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process